Episode Details

Summary

So many shoutouts in this episode of Melanoma Matters!

Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib trials, and discuss side effects associated with this class of therapy. Sapna clears her own confusion regarding the PDUFA date for the NEMO study, and James objects to the way the NEMO abbreviation was derived.

Keywords

targeted therapy, MEK inhibitors, METRIC, NEMO, pimasertib, NRAS, BRAF, melanoma, oncology, side effects, clinical trials, drug approval, patient care, cancer treatment, Owen, Dave Solit, Tom Newsom-Davis, Peter Hill

Takeaways

Targeted therapy is an important area of focus in oncology.

MEK inhibitors have been in development for over 15 years.

The NEMO trial aimed to evaluate binimetinib for NRAS mutant melanoma.

PFS as a primary endpoint in clinical trials.

Side effects of MEK inhibitors.

The NEMO trial faced challenges in gaining FDA approval despite positive results.

Sound Bites

"What gets you to an ASCO?"

Chapters

00:00 Can we get James to go shirtless (req fr Owen the Trainer)

04:28 MEK inhibitor trials

07:40 Dave Solit is handsome

09:50 Side Effects of MEK Inhibitors

10:52 Shoutout to Tom Newsom-Davis

12:29 Ocular Toxicity and Patient Management

16:25 METRIC study

19:33 NEMO trial

27:16 NEMO and the fate of its PDUFA date

29:03 Pimasertib: A New Player in NRAS Mutant Melanoma

34:31 Shoutout to Peter Hill & what is the #1 cause of rhabdo in Central London